Jwtherapeutics develops, manufactures, and commercializes CAR‑T and TCR‑T cell therapies for relapsed or refractory hematologic cancers, solid tumors, and autoimmune diseases. Leveraging proprietary CAR designs and a GMP‑compliant end‑to‑end production platform, it advances candidates from pre‑clinical studies through regulatory approval and partners with hospitals to deliver reimbursable cell‑therapy treatments.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
8OCMAFounders
Product
Problem
Patients with relapsed or refractory hematologic malignancies, solid tumors, and autoimmune diseases often lack effective, targeted therapies, leading to poor outcomes and limited treatment options.
Solution
Jwtherapeutics builds an integrated cell‑immune‑therapy platform that designs, manufactures, and commercializes CAR‑T (and related TCR‑T) products for these indications. The company leverages proprietary CAR constructs, scalable GMP manufacturing, and a dedicated process‑development pipeline to produce clinical‑grade cell therapies. It advances candidates through pre‑clinical studies, IND‑enabling work, and pivotal trials, securing regulatory approvals such as FDA clearance for Relma‑cel and national market authorizations in China. By partnering with hospitals and health‑care systems, Jwtherapeutics delivers approved cell‑therapy products to patients under reimbursable pathways.
Target Audience
Primary customers are oncologists, hematologists, and rheumatologists treating relapsed or refractory cancers and autoimmune disorders, as well as hospitals and specialty infusion centers that deliver cell‑based therapies.
Features
- Proprietary CAR designs (e.g., Relma‑cel, JWCAR129) targeting B‑cell lymphomas, multiple myeloma, solid tumors, and autoimmune diseases
- End‑to‑end manufacturing facility (≈2,500 m²) with GMP‑compliant cell‑culture, viral vector production, and aseptic fill‑finish capabilities
- Scalable process‑development workflow enabling rapid scale‑out and scale‑up of cell therapy batches
- Integrated pre‑clinical and clinical development platform supporting IND filing, phase I/II trials, and regulatory submissions
- Established regulatory track record with FDA approval and Chinese NMPA listings for multiple CAR‑T products
- Partnerships with hospitals and certified treatment centers for product administration and post‑infusion monitoring